HIGHLIGHTS
- who: Sophie L. Gerritse and colleagues from the Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein Zuid, GA Nijmegen, The Netherlands have published the paper: High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors, in the Journal: Cancers Cancers 2022, 2022, 14, 14, 6061 x FOR PEER REVIEW of /2022/
- what: The authors focused the analyses on potential relations of these concentrations with treatment benefit and biological activity. As a starting point the analysis, previously . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.